But there is still more:
Febr. 11, 2004: "Today marks the beginning of a 90 patient, multicenter Phase II trial of PI-88 in combination with Taxotere® for the second-line treatment of advanced non-small cell lung cancer (NSCLC)".
So, Phase II Myeloma has been completed and currently there are 2 more Phase II trials going: Melanoma and NSCLC.
Gerry